DEFINIUM THERAPEUTICS, INC.
NASDAQ: DFTX (Definium Therapeutics, Inc.)
最近更新时间: 7小时之前28.34
-1.14 (-3.87%)
新闻情绪
AIStockmoo 评分
| 价值 30% | -1.0 |
| 资本回报低于资本成本。资本回报上升。 参考 | |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 财务健康 参考 | NA |
| 持仓估值 参考 | NA |
| 风险溢价 参考 | NA |
| 市场估值 参考 | NA |
| 时机 30% | -1.9 |
| 过去一年呈上升趋势。股价远低于52周高点。 参考 | |
| 下降趋势:股价位于均线之下,均线向下。股价已大幅低于均线。下跌日成交量较大。 参考 | |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| K线形态 参考 | NA |
| 市场情绪 20% | 0.8 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 近期新闻大多正面。 参考 | |
| 持仓情绪 参考 | NA |
| 聪明钱 20% | 3.4 |
| 机构在最新13F申报中净+8.02%的股份:216家增持,167家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化-2.3%,回补天数5.8天(FINRA)。 参考 | |
| 内部交易活动 参考 | NA |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向不一,评分因此减弱。 | |
| 不计入评分 | |
| 每股盈利大多下降。近年曾亏损。 参考 | |
| 低于中期趋势线。 参考 | |
| 股价接近其52周平均水平。5年来下跌。 参考 | |
| 短期动能下降。 参考 | |
| 股价接近阻力位。支撑与阻力水平趋降。 参考 | |
| 最终评分 | -0.01 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Definium Therapeutics, Inc. | 混合的 | - |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B | 评分 |
|---|---|---|---|---|---|
| DFTX | 5 B | - | - | 4.54 | 0.0 |
| SYRE | 9 B | - | - | 10.08 | 1.1 |
| MDGL | 9 B | - | - | 14.74 | -0.4 |
| CORT | 7 B | - | 47.78 | 8.89 | -1.5 |
| FOLD | 5 B | - | - | - | 0.0 |
| TARS | 4 B | - | - | 36.00 | 0.6 |
|
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Capital World Investors | 30 Sep 2026 | 8,255,584 |
| Octagon Capital Advisors Lp | 30 Sep 2026 | 2,511,000 |
| Alliancebernstein L.P. | 30 Sep 2026 | 1,938,303 |
该时间范围内无数据。
机构
机构持股比例: 92.20%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 216 | 29,390,198 |
| 减持 | 167 | 18,014,338 |
| 新建仓 | 70 | 8,825,116 |
| 清仓 | 70 | 9,208,628 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 9,613,993 | 5.8 |
| 15 Oct 2026 | 10,044,279 | 4.9 |
| 30 Sep 2026 | 11,344,959 | 4.9 |
| 15 Sep 2026 | 11,785,195 | 5.2 |
| 31 Aug 2026 | 9,836,400 | 5.6 |
| 14 Aug 2026 | 8,969,420 | 3.4 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
| 日期 | 类型 | 细节 |
|---|---|---|
| 20 Nov 2026 | Yahoo Finance |
Definium Therapeutics Eyes 2027 FDA Filing for LSD-Based Drug, Weighs Two Treatment Paths
Definium Therapeutics (NASDAQ:DFTX) expects to file a new drug application for its lead LSD-based treatment in the first half of 2027, though the company has not settled on whether to seek approval for generalized anxiety disorder, major depressive disorder or both at the outset. CEO Rob Barrow sai… |
| 16 Nov 2026 | Yahoo Finance |
Definium Therapeutics: 3 Key Takeaways for Long-Term Investors
Two encouraging changes from five patients hint at a pipeline beyond depression and anxiety, but the early-stage data leaves open whether DT402 can carry that weight. |
| 16 Nov 2026 | Yahoo Finance |
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Village Farms Posted Record Cannabis Revenue as International Exports Surged 75% Auxly Cannabis Delivered Record Q3 Revenue as Adjusted EBITDA Climbed 29% Key Takeaways; Psychedelic Sector Definium Therapeutics Reported Strong Q3 Results as DT120 Advanced Towards… |
| 12 Nov 2026 | Yahoo Finance |
Is Definium Therapeutics (DFTX) Fully Priced After Positive Phase 3 Results?
Definium Therapeutics has seen its stock price move sharply in recent years, and the surge now raises a straightforward question for investors who care about balance sheet strength. Is the current market value still grounded in Definium Therapeutics' book value, or has the share price pulled… |
| 11 Nov 2026 | Yahoo Finance |
How Investors May Respond To Definium Therapeutics Stock After Phase 3 Success
Definium Therapeutics reported positive Phase 3 data for DT120 in generalized anxiety disorder and major depressive disorder, alongside plans to seek FDA approval after multiple pivotal studies. Recent earnings showed ongoing net losses tied to development spend. The most distinctive angle is that… |
| 11 Nov 2026 | Yahoo Finance |
Definium Therapeutics (DFTX) Following DT120 Phase 3 Data Is The Undervalued Story Intact
Definium Therapeutics (DFTX) is back in focus after reporting third quarter results that showed a reduced quarterly net loss alongside a much larger cumulative loss for the first nine months of 2026. Definium Therapeutics has ridden a sharp re-rating over 2026, with the share price delivering a… |
| 11 Nov 2026 | Yahoo Finance |
Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies
Definium Therapeutics (NASDAQ:DFTX) plans to submit a new drug application to the U.S. Food and Drug Administration for its LSD formulation DT120 in the first half of next year, following positive results from three Phase 3 studies, Chief Medical Officer Daniel Karlin said. The company intends to s… |
| 10 Nov 2026 | Yahoo Finance |
Definium Therapeutics Inc (DFTX) (Q3 2026) Earnings Call Highlights: $1. ...
Definium Therapeutics Inc (DFTX) pairs a cash runway into 2030 with two FDA breakthrough therapy designations for DT120 and a planned first-half 2027 NDA filing, even as R&D and G&A spending climb. |
| 09 Nov 2026 | Yahoo Finance |
Definium (DFTX) Q3 2026 Earnings Call Transcript
Phase 3 wins set up a 2027 filing and a commercial push. |
| 09 Nov 2026 | Yahoo Finance |
What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call
Definium Therapeutics (NASDAQ:DFTX) plans to file a new drug application for its psychiatric treatment candidate DT120 ODT in the first half of 2027, following positive results from three Phase 3 studies in generalized anxiety disorder and major depressive disorder, executives said on the company’s… |
| 09 Nov 2026 | Yahoo Finance |
Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
NEW YORK, November 09, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company") (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported… |
| 09 Nov 2026 | Yahoo Finance |
Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK, November 09, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of… |
| 04 Nov 2026 | Yahoo Finance |
Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
NEW YORK, November 04, 2026--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced four… |
| 03 Nov 2026 | Yahoo Finance |
Definium Therapeutics to Participate at Upcoming Investor Conferences
NEW YORK, November 03, 2026--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that… |
| 29 Oct 2026 | Yahoo Finance |
Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
NEW YORK, October 29, 2026--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a webcast at 4:30… |
| 19 Oct 2026 | Yahoo Finance |
Definium Therapeutics (DFTX) Stock May Trade Above Fair Value On Book Value
Definium Therapeutics has seen its share price move sharply in recent years, which puts a spotlight on whether the current US$32.97 level is supported by the book value on its balance sheet. With such a strong price story already on the table, investors are asking how much of that journey is… |
| 30 Sep 2026 | Yahoo Finance |
Jefferies Highlights Three Biotech Stocks With Blockbuster Potential
Investing.com -- Jefferies identified three biotechnology stocks that appear undervalued with strong commercial prospects despite a challenging macro environment. The firm noted that rising interest rates are pressuring small and mid-cap biotech companies, potentially shifting investor focus toward… |
| 显示更多 | ||
技术形态 中期
AI 技术分析
投资组合